Back to search

University of Ioannina

Σχεδιασμός, σύνθεση και βιολογικός έλεγχος νέων βιοδραστικών ενώσεων, αναλόγων της Νιλοτινίβης (Νilotinib) και της Ιματινίβης (Ιmatinib) ως αναστολέων πρωτεϊνικών κινασών και της πολυμεράσης της πόλυ­(ΑDP­ριβόζης) (PARP)­: ανάπτυξη νέας βελτιωμένης ολικής σύνθεσης του αναστολέα Rucaparib

Abstract

dc:description

Protein kinase are enzymes that modifies other proteins by adding phosphate group from ATP to them, a process which is called phosphorylation. Kinases are known to mediate and regulate the majority of cellular pathways, including survival, proliferation, transcription, differentiation, apoptosis and many other cellular processes. Phosporylation of proteins results in a functional change of the target substrate of protein via the alteration of the enzyme activity. Deregulation of protein kinases lead to alterations in functions of these enzymes which may launch series of pathological diseases and cancer, including malignant disorders such aschronic myeloid leukemia, gastrointestinal stromal tumors as well as non-malignant diseases. There are indisputable evidence that protein kinases are a validated drug targets for treatment of various diseases including cancer. The tremendous appeal for development of small low-molecule weight inhibitors as a therapeutic agents against many diseases constitutes a major target by many companies. Beyond the role of protein kinases in cellular processes, a very important family of proteins are poly(ADP-ribose)polymerases, PARPs. These polymerases are enzymes that catalyze the synthesis of negatively charged and branched polymers of ADP ribose (PAR) attached to other proteins, using as a substrate NAD+. Another objective of this present Phd thesis is stated the design, synthesis, biological evaluation of a new series of analogues of Nilotinib and Imatinib, which constitute structurally related compounds to Tasigna and Gleevec with specific modifications. Besides the mentioned before modifications on the primary structrure of Nilotinib and Imatinib, another major aim of the present PhD thesis is to provide a more effective and low cost total improved synthesis for the preparation of the imatinib and nilotinib analogues, compared to the described synthetic process by Novartis. We achieved a higher overall yield and a low cost synthetic process in which all the intermediate compounds and also the final compounds were easily isolated and obtained in higher yields compared to Novartis synthetic process. Finally, the new inhibitors were purified with column chromatography, considering that it is obligatory a high purity of them in the biological tests and were fully characterized by IR, 1H-NMR, 13C-NMR spectroscopy and high resolution mass spectrometry (ESI-HRMS).

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2020

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Ntemou, Nikoleta
  • Ντέμου, Νικολέτα

Subjects

dc:subject × 20

Rights

dc:rights
Statement dc:rights
  • BY
Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/48003

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Ntemou, Nikoleta; Ντέμου, Νικολέτα. Σχεδιασμός, σύνθεση και βιολογικός έλεγχος νέων βιοδραστικών ενώσεων, αναλόγων της Νιλοτινίβης (Νilotinib) και της Ιματινίβης (Ιmatinib) ως αναστολέων πρωτεϊνικών κινασών και της πολυμεράσης της πόλυ­(ΑDP­ριβόζης) (PARP)­: ανάπτυξη νέας βελτιωμένης ολικής σύνθεσης του αναστολέα Rucaparib. University of Ioannina, 2020. http://hdl.handle.net/10442/hedi/48003